Nominated as Technology Company of the Year in Celebration of Achievement and Innovation for Life Sciences Leaders
Horsham, Pa. May 25, 2022 — Clinical ink, a global life science technology company, was nominated for Technology Company of the Year by the Philadelphia Alliance for Capital and Technologies (PACT) during the organization’s 29th annual Enterprise Awards, held May 24, 2022.
Clinical ink was recognized for pioneering and continually innovating direct data capture technologies, which allow for the measurement of clinical trial patients both in and outside the clinic. Notably, earlier in 2022 the company announced research that strengthens its standing as a critical partner in advancing clinical development for Parkinson’s disease, via the collection of patient data via sensors and at-home wearable assessments.
Clinical ink was nominated by a panel of judges consisting of executives from the area’s largest life science and healthcare companies, healthcare and technology focused investors, and startup executives.
“We are incredibly honored to be among the nominees,” says Chief Executive Officer Ed Seguine. “At Clinical ink, our work is rooted in enabling clinical discovery by bringing data, technology, and patient science together. We are proud to be recognized for our technological prowess, as well as our deep industry knowledge and scientific expertise. We will only continue to advance our offerings, ensuring that our partners can better power patient outcomes.”
Over the past five years, Clinical ink has experienced 40% annual revenue growth. By consistently delivering technology solutions that allow for the collection of complex clinical data, the company has established relationships with the largest and most innovative pharmaceutical sponsors in the industry.
About Clinical ink
Clinical ink is the global life science company that brings data, technology, and patient science together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.
